New study first to confirm Sandostatin LAR controls tumor growth in patients with rare gastrointestinal tumors
Links shared publicly online about this topic.
- 2,301total visits
New study first to confirm Sandostatin LAR controls tumor growth in patients with rare gastrointestinal tumors
Basel, January 13, 2009 - Sandostatin LAR (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine tumors (NETs) of the midgut, according to interim data presented today at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology.
View full resource at novartis.com
Tags: Acromegaly Medication, Cancer, Sandostatin, Oncology
Most Recently Shared on January 27, 2009 at 11:40 am By:
New study first to confirm Sandostatin® LAR® controls tumor growth in patients with rare gastrointestinal tumors : http://twurl.nl/6w8wgf
Advertisement
